Merck Sharp Dohme patents expiration
1. Belsomra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7951797 | MERCK SHARP DOHME | Substituted diazepan orexin receptor antagonists |
Nov, 2029
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098892 | MERCK SHARP DOHME | Solid dosage formulations of an orexin receptor antagonist |
May, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jan 29, 2023 |
Drugs and Companies using SUVOREXANT ingredient
Market Authorisation Date: 13 August, 2014
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
BELSOMRA family patents
2. Clarinex D 24 Hour patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7820199 | MERCK SHARP DOHME | Stable extended release oral dosage composition |
Mar, 2022
(1 year, 6 months ago) | |
| US6979463 | MERCK SHARP DOHME | Stable extended release oral dosage composition |
Mar, 2022
(1 year, 6 months ago) | |
|
US7820199 (Pediatric) | MERCK SHARP DOHME | Stable extended release oral dosage composition |
Sep, 2022
(a year ago) | |
Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient
Market Authorisation Date: 03 March, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
CLARINEX D 24 HOUR family patents
3. Dutrebis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820660 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(4 days from now) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(11 months ago) | |
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(11 months ago) | |
|
US7217713 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
|
US7435734 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(6 months from now) | |
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 06 February, 2015
Treatment: Treatment of hiv-1 infection
Dosage: TABLET;ORAL
DUTREBIS family patents
4. Isentress patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(4 days from now) | |
| US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(11 months ago) | |
| US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(11 months ago) | |
|
US7435734 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
|
US7217713 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(5 months ago) | |
|
US7169780 (Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(6 months from now) | |
|
US7754731 (Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
| US9649311 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(7 years from now) | |
|
US9649311 (Pediatric) | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(7 years from now) | |
| US10772888 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(8 years from now) | |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Treatment of hiv infection; Integrase inhibition for the treatment of hiv infection; Treatment of hiv-1 infection
Dosage: TABLET, CHEWABLE;ORAL
ISENTRESS family patents
5. Janumet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| US8414921 | MERCK SHARP DOHME | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jul, 2028
(4 years from now) | |
|
US8414921 (Pediatric) | MERCK SHARP DOHME | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jan, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Feb 12, 2023 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl p...
Dosage: TABLET;ORAL
JANUMET family patents
6. Janumet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Feb 12, 2023 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
7. Januvia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Dec 4, 2023 |
| Pediatric Exclusivity (PED) | Jun 4, 2024 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering ...
Dosage: TABLET;ORAL
JANUVIA family patents
8. Juvisync patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8168637 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes |
Jun, 2022
(1 year, 3 months ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Oct, 2026
(3 years from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatm...
Dosage: TABLET;ORAL
JUVISYNC family patents
9. Noxafil patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(5 years from now) | |
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(7 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(7 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 31, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2028 |
| New Indication (I) | Jun 17, 2024 |
Drugs and Companies using POSACONAZOLE ingredient
Market Authorisation Date: 13 March, 2014
Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of a...
Dosage: SOLUTION;INTRAVENOUS
NOXAFIL family patents
10. Prevymis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE46791 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(7 months from now) | |
| US8513255 | MERCK SHARP DOHME | Substituted dihydroquinazolines |
May, 2024
(7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10603384 | MERCK SHARP DOHME | Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative |
Feb, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Jun 5, 2030 |
| New Indication (I) | Jun 5, 2026 |
Drugs and Companies using LETERMOVIR ingredient
Market Authorisation Date: 08 November, 2017
Treatment: NA
Dosage: TABLET;ORAL
PREVYMIS family patents
11. Segluromet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439902 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| US9308204 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
SEGLUROMET family patents
12. Steglatro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLATRO family patents
13. Steglujan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 2 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(3 years from now) | |
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(8 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| US9439901 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| US9308204 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLUJAN family patents
14. Temodar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623868 | MERCK SHARP DOHME | Processes of making and using pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(7 months ago) | |
| US7786118 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents |
Feb, 2023
(7 months ago) | |
| US6987108 | MERCK SHARP DOHME | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same |
Sep, 2023
(20 days ago) | |
Drugs and Companies using TEMOZOLOMIDE ingredient
Market Authorisation Date: 27 February, 2009
Treatment: NA
Dosage: POWDER;INTRAVENOUS
TEMODAR family patents
15. Verquvo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10736896 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US8420656 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US9604948 | MERCK SHARP DOHME | Process for preparing substituted 5-fluoro-1H-pyrazolopyridines |
Nov, 2032
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9993476 | MERCK SHARP DOHME | Substituted 5-flouro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US11439642 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| US8921377 | MERCK SHARP DOHME | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 19, 2026 |
Drugs and Companies using VERICIGUAT ingredient
NCE-1 date: 2025-01-19
Market Authorisation Date: 19 January, 2021
Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...
Dosage: TABLET;ORAL
VERQUVO family patents
16. Victrelis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43298 | MERCK SHARP DOHME | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
Dec, 2024
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8119602 | MERCK SHARP DOHME | Administration of HCV protease inhibitors in combination with food to improve bioavailability |
Mar, 2027
(3 years from now) | |
| US7772178 | MERCK SHARP DOHME | Pharmaceutical formulations and methods of treatment using the same |
Nov, 2027
(4 years from now) | |
Drugs and Companies using BOCEPREVIR ingredient
Market Authorisation Date: 13 May, 2011
Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in...
Dosage: CAPSULE;ORAL
VICTRELIS family patents
17. Welireg patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 13, 2026 |
| Orphan Drug Exclusivity (ODE) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 2025-08-13
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with von hippel-lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not r...
Dosage: TABLET;ORAL
WELIREG family patents
18. Zepatier patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7973040 | MERCK SHARP DOHME | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
Jul, 2029
(5 years from now) | |
| US8871759 | MERCK SHARP DOHME | Inhibitors of hepatitis C virus replication |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 9, 2024 |
Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET;ORAL
ZEPATIER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic